AACR Special Conference on
Tumor Immunology and Immunotherapy
October 18-21, 2024 | Boston, MA

AACR
American Association
for Cancer Research®

2403026E

Current as of September 20, 2024

Poster Session A (To be presented on October 19 from 6-8:15 p.m.)

A001 **Epithelial cancers demonstrate IL34-associated dysfunction of Langerhans cells**. Thi Viet Trinh Dang. Frazer Institute, The University of Queensland, Brisbane, QLD, Australia.

A002 **Ifetroban blocks the metastatic intravascular niches by blocking the platelet activation through thromboxane A2 cascade.** Veeresh Toragall. University of Mississippi, Oxford, MS, United States.

A003 **DPEP1 maintains microsatellite stability in colorectal cancer at the tumor microenvironment interface**. Sarah Glass. Vanderbilt University, Nashville, TN, United States.

A004 **Fc-optimized agonistic CD40 antibody induces tumor rejection and systemic antitumor immunity - From the bench to the bedside and back**. Polina Weitzenfeld. The Rockefeller University, New York, NY, United States.

A005 **Reduction in Surgical Interventions for the Treatment of Recurrent Respiratory Papillomatosis by INO-3107 is Associated with Enriched Macrophage, Dendritic cell and T cell Signatures in Patient Airways**. Matthew Morrow. Inovio Pharmecuticals, Plymouth Meeting, PA, United States.

A006 **Tissue resident memory (TRM) T cells and dendritic cells form an in situ archetype for improved response to immune checkpoint therapy in metastatic melanoma**. Paul Neeson. Peter MacCallum Cancer Center, Melbourne, Australia.

A007 **Prognostic significance of complete blood count values and tumor-infiltrating lymphocytes in non-small cell lung cancer patients undergoing immune checkpoint inhibitor therapy**. Katiane Tostes. Barretos Cancer Hospital, Barretos, Brazil.

A008 **Better outcomes for ovarian cancer associated with the detection of anti-EBV TCR CDR3s: Potential relevance to diffuse large B-cell lymphoma**. Nandini Goel. USF Morsani College of Medicine, TAMPA, FL, United States.

A009 **T cell immune landscape in melanoma patients before and post immune checkpoint blockade treatment**. Ying Luo. UT Southwestern Medical Center, Dallas, TX, United States.

A010 **Tumor-reactive T cell clonal dynamics across treatment time points drive resistance and progression to frontline chemoimmunotherapy in advanced gastric cancer**. Samuel Wright. Broad Institute of MIT and Harvard, Cambridge, MA, United States.

A011 **A TROP2/Claudin program mediates immune exclusion to impede checkpoint blockade in breast cancer**. Bogang Wu. Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, United States.

American Association for Cancer Research® Special Conference in Cancer Research
TUMOR IMMUNOLOGY AND IMMUNOTHERAPY
In association with the Cancer Immunology (CIMM) Working Group
October 18-21, 2024 | Boston, MA

1

AACR Special Conference on
Tumor Immunology and Immunotherapy
October 18-21, 2024 | Boston, MA

AACR
American Association
for Cancer Research®

2403026E

A012 **Stratifying immune subtypes in real-world HNSCC cohort to identify those with better outcomes to standard treatment regimens**. Merzu Belete. Genmab, Princeton, NJ, United States.

A013 **Transcription initiation and its regulation in mouse L1s**. Wenfeng An. South Dakota State University, Brookings, SD, United States.

A014 **Targeting the KDEL receptor 2 confers tumor regression in the absence of T cells**. Shakti Pattanayak. case western reserve university, cleveland, OH, United States.

A015 **A synergistic combination of a novel mTORC1-activator with proteasome inhibitor confers a remission in acute myeloid leukemia**. Shakti Pattanayak. Case Western Reserve University, Cleveland, OH, United States.

A016 **Bitter taste receptor T2R5 regulates cell viability and apoptosis in head and neck squamous cell carcinoma**. Sarah Sywanycz. University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, United States.

A017 **Identifying proliferative and immune-modulatory drivers of small cell lung cancer (SCLC)**. Myung Chang Lee. Genentech, Inc., South San Francisco, CA, United States.

A018 **Deconvolving the cell-specific actions of SHP2 inhibitors in the lung cancer tumor microenvironment reveals requirement for SHP2 in B-regulatory cell development**. Benjamin Neel. NYU Grossman School of Medicine, New York, NY, United States.

A019 **Prostaglandin E$_2$-EP2/EP4 signaling induces immunosuppression in human cancer by impairing bioenergetics and ribosome biogenesis in immune cells infiltrating human tumor**. Siwakorn Punyawatthananukool. Kyoto University, Kyoto, Japan.

A020 **The highly predictive 3D Cell Co-Culture Model for Immunotherapy studies**. Marcin Krzykawski. Real Research, Krakow, Poland.

A021 **A cancer immunotherapy modality based on dendritic cell reprogramming in vivo**. Xavier Catena. Asgard Therapeutics AB, Lund, Sweden.

A022 **Potentiating the antitumor response of CD8+ T cells by targeting SQLE-mediatedcholesterol metabolism reprogramming in hepatocellular carcinoma**. Shuang Qiao. Sun Yat-Sen University Cancer Center, guangzhou, China (Mainland).

A023 **Evaluating Desmocollin-3 and tumor infiltrating lymphocytes in solid tumors**. Bakulesh Khamar. Cadila Pharmaceuticals Ltd, Ahmedabad, India.

American Association for Cancer Research® Special Conference in Cancer Research
TUMOR IMMUNOLOGY AND IMMUNOTHERAPY
In association with the Cancer Immunology (CIMM) Working Group
October 18-21, 2024 | Boston, MA

2

A024 **POSTPRANDIAL CHANGES TO SYSTEMIC METABOLISM IMPRINT DURABLE CHANGES ON T CELL IMMUNE RESPONSES**. Alok Kumar. University of Pittsburgh, Pittsburgh, PA, United States.

A025 **Novel workflow for characterizing T-cell functional heterogeneity in response to checkpoint inhibitors**. Gary Schroth. Cellanome, Foster City, CA, United States.

A026 **Lysosomal ion gradients are key determinants of T cell metabolism and function**. Robert Eil. Oregon Health & Science University, Portland, OR, United States.

A027 **Spatial transcriptomics to profile the non-small cell lung cancer tumor microenvironment and identify novel predictive biomarkers for checkpoint blockade**. Christina Cho. Yale University, New Haven, CT, United States.

A028 **Cycling T regulatory cells architect an immune escape hub duringin situto invasive breast carcinoma transition**. Triet Bui. Dana Farber Cancer Institute, Boston, MA, United States.

A029 **Preferential ability of IL-7 versus IL-2 to restore effector T cell responses in the presence of regulatory T cells assessed using MR-MCTM assays in vitro**. Omar Qureshi. Celentyx Ltd, Birmingham, United Kingdom.

A030 **CD4 neoantigen mRNA vaccine enhances endogenous CD8 responses and tumor control**. Camille-Charlotte Balanca. Genentech, Inc, South San Francisco, CA, United States.

A031 **Unhelpful CD4 help: Removal of conventional CD4+ T cells promotes priming of tumor antigen-specific CD8 T cells in the context of CD4-depletion therapy**. Christo P. Dragnev. Dartmouth Cancer Center, Lebanon, NH, United States.

A032 **KRAS mutations have distinct effects on the tumor immune microenvironment inpancreatic cancer**. Despina Siolas. Weill cornell Medicine, Long Island City, NY, United States.

A033 **Pro-inflammatory tumor cells drive CD4+ T cell localization within heterogeneous tumors**. Robert Letchworth. University of Utah, Salt Lake City, UT, United States.

A034 **Distinct CD4+ T cell subpopulations as predictive biomarkers for anti-PD-1 and chemotherapy response in advanced NSCLC**. Kenneth Gollob. Albert Einstein Israelite Hospital, Sao Paulo, Brazil.

A035 **Lymph node colonization reprograms Treg responses to generate systemic tolerance and promote distant metastasis**. Nathan Reticker-Flynn. Stanford University, Stanford, CA, United States.

American Association for Cancer Research® Special Conference in Cancer Research
TUMOR IMMUNOLOGY AND IMMUNOTHERAPY
In association with the Cancer Immunology (CIMM) Working Group
October 18-21, 2024 | Boston, MA

3

A036 **Combining data-independent acquisition and targeted immunopeptidomics to enhance neoepitope discovery**. Angelika Riemer. German Cancer Research Center (DKFZ), Heidelberg, Germany.

A037 **Enhanced anti-tumor activity through targeted immunotherapy combined with mutant KRAS inhibition in pancreatic cancer**. Amanda Creech. UCLA, Los Angeles, CA, United States.

A038 **Antigen Presentation By Cancer-Associated Fibroblasts**. Eralda Kina. University of Montreal, Montreal, QC, Canada.

A039 **ONCOGENIC RAS DOSAGE ALTERS SENESCENT IMMUNE RESPONSE AND INFLUENCES TUMOUR INITIATION**. Haoran Zhu. CRUK Cambridge Insititute, Cambridge, United Kingdom.

A040 **AXL limits the mobilization of cholesterol to regulate dendritic cell maturation and the immunogenic response to cancer**. Meriem Belabed. Icahn school of medicine at mount sinai, New York, NY, United States.

A041 **A microphysiological system to quantify the interactions of human neutrophil subpopulations with pancreatic tumor spheroids**. Shuai Shao. The University of Texas at Dallas and UT Southwestern Medical Center, Richardson, TX, United States.

A042 **Common gamma-chain signaling in NK cells promotes their Flt3L-dependent support of cDC1s in melanoma**. Shayan Avanessian. Fred Hutchinson Cancer Center, Seattle, WA, United States.

A043 **Costimulation by type 1 dendritic cells facilitates the differentiation of non-exhausted anti-tumor T cells**. Ellen Duong. Genentech, South San Francisco, CA, United States.

A044 **Meta-analysis of adoptive natural killer cell transfer immunotherapy against solid cancers in human patients**. Eric Jou. University of Oxford, Oxford, United Kingdom.

A045 **PSB120, a LILRB2 specific antibody enhances sensitivity to Gemcitabine through an HLA-G independent mechanism**. YuFeng Peng. Sound Biologics, Bothell, WA, United States.

A046 **Tissue-of-origin determines immune cell heterogeneity and response to therapy via unique tumor cell-intrinsic factors**. Jane Xie. University of Pennsylvania, Philadelphia, PA, United States.

A047 **Activation of conventional type 2 dendritic cells (cDC2) by anti-CD47 may enhance antitumor T cell function in mouse liver cancer models**. Chiun Hsu. Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan (Greater China).

American Association for Cancer Research® Special Conference in Cancer Research
TUMOR IMMUNOLOGY AND IMMUNOTHERAPY
In association with the Cancer Immunology (CIMM) Working Group
October 18-21, 2024 | Boston, MA

4

AACR Special Conference on
Tumor Immunology and Immunotherapy
October 18-21, 2024 | Boston, MA

AACR
American Association
for Cancer Research
2403026E

A048 **The Loss of Cholesterol Efflux Pump ABCA1 Skews Macrophages Towards a Pro-tumor Phenotype and Facilitates Breast Cancer Progression**. Shruti Bendre. University of Illinois at Urbana Champaign, Champaign, IL, United States.

A049 **NKG2D and NKp30 activating receptors drive allogeneic natural killer cell responsiveness against pancreatic cancer**. Stacey Lee. Dalhousie University, Halifax, NSW, Canada.

A050 **Unraveling Immune Dysregulation in Acute Myeloid Leukemia: Insights from Whole Exome and Transcriptome Analysis**. HARSH GOEL. Laboratory Oncology Unit, Dr.B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India, India.

A051 **Bitter agonists increase macrophage phagocytosis of head and neck squamous cell carcinoma cells**. Brianna Hill. University of Pennsylvania, Philadelphia, PA, United States.

A052 **RNF43 p.G659fs mutation in MSI-high colorectal cancer leads to natural killer cell dysfunction**. Pushpamali De Silva. Dana-Faber Cancer Institute, Boston, MA, United States.

A053 **Tumor-localized myeloperoxidase enhances tumor chemoresistance, migration, and invason.** Rita Loudermilk. University of California San Francisco, San Francisco, CA, United States.

A054 **Recruiting innate immune cells universally: Development of a novel universal innate cell engager for cancer-immunotherapy**. Idil Hutter-Karakoc. Roche, Zurich, Switzerland.

A055 **CD47 predominates over CD24 as a macrophage immune checkpoint in cancer**. Anna Meglen. Whitehead Institute for Biomedical Research, Cambridge, MA, United States.

A056 **TNFR2 is a novel marker of exhaustion and TNFR2 blockade improves subcutaneous tumor control**. Alexandra Hoyt-Miggelbrink. Duke University, Durham, NC, United States.

A057 **Therapeutic modality, antitumor efficacy and immune safety for targeting innate immune checkpoint TREX1 as cancer immunotherapy**. Cong Xing. UT Southwestern Medical Center, Dallas, TX, United States.

A058 **Oncolytic adenovirus induces potent anti-tumor efficacy via robust activation of immune cells in bladder cancer**. Yunlim Kim. Asan Institute for Life Sciences, Asan Medical Center, Seoul, Korea, Republic of.

A059 **Uncovering Bystander Killing Mechanisms of Trastuzumab Deruxtecan (T-DXd): Effective Extracellular Payload Release via Cathepsin L in HER2-low Breast Cancer.** Li-Chung Tsao. Duke University, Durham, NC, United States.

American Association for Cancer Research® Special Conference in Cancer Research
TUMOR IMMUNOLOGY AND IMMUNOTHERAPY
In association with the Cancer Immunology (CIMM) Working Group
October 18-21, 2024 | Boston, MA

5

AACR Special Conference on
Tumor Immunology and Immunotherapy
October 18-21, 2024 | Boston, MA

AACR
American Association
for Cancer Research'
2403026E

Poster Session B (To be presented on October 20 from 6-8:15 p.m.)

B001 **Removal of interstitial hyaluronan facilitates subcutaneous administration and lymphatic delivery of anti-CTLA4 antibody and improves anti-tumor efficacy**. Gracia Gracia. Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Australia.

B002 **HIF-2A inhibition in adaptive immunity against cancer growth**. Katya Frazier. Merck & Co., Boston, MA, United States.

B003 **Validating PTPN22 as a cancer-agnostic immunotherapeutic target**. Jayalaxmi Suresh Babu. Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, United States.

B004 **Identifying response factors to PD1-IL2v therapy**. Amrita Manchala. Roche Glycart AG, Zürich, Switzerland.

B005 **Denosumab Enhances Cytotoxic T Cell Infiltration by supressing SPP1 Expression in Giant Cell Tumour of Bone**. Zezhuo Su. Department of Orthopaedics and Traumatology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, Hong Kong (Greater China).

B006 **Ceralasertib enhance efficacy of anti-PDL1 treatment by modulating the tumor microenvironment in a IFNAR I dependent manner.** Emilio Sanseviero. AstraZeneca, Gaithersburg, MD, United States.

B007 **Upregulation of PD-L1 as a mechanism of resistance to CD47 inhibition in non-small cell lung cancer**. Asa Lau. University of Toronto, Toronto, ON, Canada.

B008 **Rescuing neoantigen-specific CD8+ T-cell immunity from tumor-microenvironment-mediated immunosuppression in pancreatic cancer**. Jeremy Jacox. Yale University, New Haven, CT, United States.

B009 **Enhancing Antitumor Immune Responses: Trastuzumab Deruxtecan (T-DXd) Induces Immunogenic Cell Death and Phagocytosis, Synergizing with CD47/SIRPα Checkpoint Blockade**. Li-Chung Tsao. Duke University, Durham, NC, United States.

B010 **A PD-L1 x CD3 bispecific antibody enhances the anti-tumor efficacy of regorafenib in pre-clinical colon cancer models**. Izuchukwu Okpalanwaka. Texas Tech University Health Sciences Center, Abilene, TX, United States.

B011 **MTA-cooperative PRMT5 inhibition (BMS-986504) induces MTAP del tumor cell-intrinsic immune evasion and regulation**. Josephine Hai. Bristol Myers Squibb, Cambridge, MA, United States.

American Association for Cancer Research® Special Conference in Cancer Research
TUMOR IMMUNOLOGY AND IMMUNOTHERAPY
In association with the Cancer Immunology (CIMM) Working Group
October 18-21, 2024 | Boston, MA

6

AACR Special Conference on
Tumor Immunology and Immunotherapy
October 18-21, 2024 | Boston, MA

AAC-R
American Association
for Cancer Research®

2403026E

B012 **Reviving exhausted T cells in pediatric B-cell acute lymphoblastic leukemia**.
Tanmaya Atre. BC Children's Hospital Research Institute, Vancouver, BC, Canada.

B013 **Evaluation of anti-PD-L1 and anti-VEGF-A combinatorial immunotherapy in preclinical murine liver cancer models**. Shing Kam. German Cancer Research Center (DKFZ), Heidelberg, Germany.

B014 **Leveraging T cell anti-tumor immunity to enhance the efficacy of Ras inhibition in pancreatic cancer**. Tanner Dalton. Columbia University Irving Medical Center, New York, NY, United States.

B015 **Wnt inhibition improves the efficacy of anti-PD-1 therapy in glioblastoma**. Somin Lee. Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States.

B016 **Lactate uptake through MCT11 enforces dysfunction in terminally exhausted T cells**. Ronal Peralta. University of Pittsburgh, Pittsburgh, PA, United States.

B017 **Chronic stress signaling in disseminated tumor cells promotes immune evasion in breast cancer metastasis**. Monica Cassandras. Dana-Farber Cancer Institute, Boston, MA, United States.

B018 **CCL24+ monocytes drives resistance to anti-PD-L1 blockade in hepatocellular carcinoma**. HAIJING DENG. The University of HongKong, Hongkong, Hong Kong (Greater China).

B019 **Investigating the role of antigen-presenting fibroblasts in the tumor microenvironment of non-small cell lung cancer**. Rachael Hinshaw. University of Michigan, Ann Arbor, MI, United States.

B020 **Investigating the immunomodulatoryeffects ofcombined histotripsy and N-dihydrogalactochitosan: Anovel non-invasive therapeutic strategyforosteosarcoma.** Ny Luong. Virginia-Maryland College of Veterinary Medicine, Blacksburg, VA, United States.

B021 **A preclinical murine model investigation; Focused ultrasound ablation of osteosarcoma induces local and systemic immunomodulation**. Ny Luong. Virginia-Maryland College of Veterinary Medicine, Blacksburg, VA, United States.

B022 **Tumoral GLI1 controls theresident innate and adaptive tumor immune microenvironment in triple negative breast cancer**. Aidan Gray. University of Toronto, Toronto, ON, Canada.

B023 **Immunomodulatory telodendrimer nanomedicine in treating ovarian cancer**. Hadil Gadelrab. SUNY Upstate Medical University, Syracuse, NY, United States.

American Association for Cancer Research® Special Conference in Cancer Research
TUMOR IMMUNOLOGY AND IMMUNOTHERAPY
In association with the Cancer Immunology (CIMM) Working Group
October 18-21, 2024 | Boston, MA

7

AACR Special Conference on
Tumor Immunology and Immunotherapy
October 18-21, 2024 | Boston, MA

AACR
American Association
for Cancer Research®

2403026E

B024 Causal Association between Wnt/β-catenin Gene expression with Cervical Cancer Risk: Two Sample Mendelian Randomization (MR). Woong Ju. Ewha Womans University Seoul Hospital, Seoul, Korea, Republic of.

B025 A T cell engager targeting cancer associated fibroblasts inhibits tumor growth and modulates the tumor microenvironment. Sarah O'Brien. Boehringer Ingelheim, Ridgefield, CT, United States.

B026 Modulation of signalling cross-talk between pJNK and pAKT generates optimal apoptotic response. Baishakhi Tikader. Indian Institute of Science, Bengaluru, Bangalore, KS, India.

B027 Transcriptional and chromatin accessibility landscapes of hematopoietic progenitors in a mouse model of breast cancer. Changxu Fan. Washington University School of Medicine, St. Louis, MO, United States.

B028 Claudin-18 expression (using the 43-14A antibody kit) in pancreatic ductal adenocarcinoma: Assessment of a potential clinical biomarker for immunotherapy with zolbetuximab. Riley Arseneau. Dalhousie University, Halifax, NSW, Canada.

B029 Desmocollin-3: a promising prognostic biomarker. Bakulesh Khamar. Cadila Pharmaceuticals Pvt Ltd, Ahmedabad, United States.

B030 IL-27 expressing oncolytic HSV prolongs survival in a syngeneic murine malignant glioma model in a CD8 T cell-dependent manner. Alexia Martin. Nationwide Children's Hospital, Columbus, OH, United States.

B031 TCR signal strength drives tumor-specific CD8 T cell differentiation. Sandra Carson. Weill Cornell Graduate School, Memorial Sloan Kettering Cancer Center, New York, NY, United States.

B032 Novel immunotherapy approach for metastatic triple-negative breast cancer. Kyle Rajapakse. University of Virginia, Charlottesville, VA, United States.

B033 Excessive Chimeric Antigen Receptor signaling correlates with poor clinical outcomes. Isabella Draper. Seattle Children's Research Institute, Seattle, WA, United States.

B034 Assessing the cytotoxic potential of novel CAR-NK cells targeting glioblastoma stem cell antigens. Vitoria Lima. University of São Paulo, São Paulo, Brazil.

B035 Enhanced tumor infiltration and functionality of anti-GPC3 CAR-T cells in hepatocellular carcinoma through locoregional administration. Jue WANG. The Chinese University of Hong Kong, Hong Kong, Hong Kong (Greater China).

American Association for Cancer Research® Special Conference in Cancer Research
TUMOR IMMUNOLOGY AND IMMUNOTHERAPY
In association with the Cancer Immunology (CIMM) Working Group
October 18-21, 2024 | Boston, MA

8

AACR Special Conference on
Tumor Immunology and Immunotherapy
October 18-21, 2024 | Boston, MA

AACR
American Association for Cancer Research'
2403026E

B036 **CRISPR/Cas9 Engineering of Next-Generation Armoured CAR T Cells**. Amanda Chen. Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.

B037 **AB-2100, a PSMA-inducible CA9-specific CAR T cell product intended for the treatment of ccRCC provides long-term tumor responses in preclinical mouse model**. Suchismita Mohanty. Arsenal Bio, South San Francisco, CA, United States.

B038 **Competition for dendritic cells limits engineered TCR-T cell activation in tumor-draining lymph nodes and impairs synergy with PD-L1 blockade**. Sam Nutt. Fred Hutch Cancer Center, Seattle, WA, United States.

B039 **Elucidating the tumor-driven mechanisms of resistance to immunotherapies in pancreatic cancer through in vivo CRISPR/Cas9 knockout screening**. Julia Froese. Koch Institute at MIT, Cambridge, MA, United States.

B040 **High-Content Screening to Enhance the Preclinical Development of Immunotherapies, Validated for 100 Patient-Derived Organoids**. Gera Goverse. Crown Bioscience, Amsterdam, Netherlands.

B041 **Non-clinical Development of T-Plex Component TSC-203-A0201: A TCR-T Cell Therapy Directed to an HLA-A*02:01-Restricted PRAME Epitope for the Treatment of Solid Tumors**. NIVYA SHARMA. TScan therapeutics, Waltham, MA, United States.

B042 **A bioengineered mammalian transposon for dual targeting CAR T cells: Addressing antigen escape in hematological cancers**. Francisco Navarro. SalioGen Therapeutics, Lexington, MA, United States.

B043 **CD3ζ ITAM diversity determines chimeric antigen receptor signaling and function**. Shubhabrata Majumdar. Baylor College of Medicine, University of Utah, Salt Lake City, UT, United States.

B044 **Development of Tumour-specific CD146 CAR-T Cells for Targeted Cancer Immunotherapy of Solid Tumours**. Erez Uzuner. University of Manchester, Manchester, United Kingdom.

B045 **Tumor- and T-cell-centric parameters shape the immunogenicity of cancer neoantigens and determine productive antitumor CD8+ T cell responses**. Jessica Schmeling. Medical College of Wisconsin, Milwaukee, WI, United States.

B046 **Enhanced immune cell engineering utilizing a novel, effective intracellular delivery method for introduction of diverse cargo types**. Jacquelyn Hanson. Portal Biotechnologies, Watertown, MA, United States.

B047 **Predictive Molecular Signatures of Tumor Reactivity from Antigen SpecificTumor Infiltrating Lymphocytes (TILs) in Human Papillomavirus (HPV)-Positive Oropharyngeal**

American Association for Cancer Research® Special Conference in Cancer Research
TUMOR IMMUNOLOGY AND IMMUNOTHERAPY
In association with the Cancer Immunology (CIMM) Working Group
October 18-21, 2024 | Boston, MA

9

AACR Special Conference on
Tumor Immunology and Immunotherapy
October 18-21, 2024 | Boston, MA

AACR
American Association
for Cancer Research
2403026E

Carcinoma (OPC). Xianli Jiang. The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

B048 **Next Generation Binding: Measuring Cell Avidity to Fully Characterize Cell-Cell Interactions and Understand Mechanism of Action for Cellular Therapies**. Song-My Hoang. LUMICKS, Boston, MA, United States.

B049 **Interplay between tumor metabolism, vasculature, and T-cell infiltration in anti-tumor immunity**. Giorgia Colombo. Weill Cornell Medicine, New York, NY, United States.

B050 **A novel approach and model to limit cytokine release syndrome and off-tumor toxicity of synthetically enhanced CEA CAR-T cells**. Robert Eil. Oregon Health & Science University, Portland, OR, United States.

B051 **Optimally designed mRNA vaccine encoding tumor-specific antigens identified in a colorectal cancer model leads to complete tumor rejection in mice**. Marie-Pierre Hardy. IRIC, University of Montreal, Montreal, QC, Canada`.

B052 **Recombinant Listeria-Monocytogenes Vaccine Induces Anti-tumor Immune Response in Inflammatory Cell Death Machinery-Deficient Mice**. Abolaji Olagunju. Univeraity of São Paulo, São Paulo, Brazil.

B053 **Neoadjuvant Personalized Viral Vectored vaccines are highly effective against tumor relapse in checkpoint inhibitor resistant murine models**. Anna Morena D'Alise. Nouscom Srl, Rome, Italy.

B054 **Enhanced Antitumor Efficacy of Oncolytic Adenovirus Co-Expressing IL-12 and shVEGF Combined with Anti-PD-1 in Renal Cell Carcinoma**. Yunlim Kim. Asan Institute for Life Sciences, Asan Medical Center, Seoul, Korea, Republic of.

B055 **A pan-HLA HPV16 T cell epitope repertoire – validated by immunopeptidomics and immunogenicity analysis – for therapeutic vaccine design**. Kathrin Wellach. German Cancer Research Center (DKFZ); German Center for Infection Research (DZIF), Heidelberg, Germany.

B056 **Personalized RNA neoantigen vaccines induce long-lived CD8+ T effector cells in pancreatic cancer**. Pablo Guasp. Memorial Sloan Kettering Cancer Center, New York, NY, United States.

B057 **An optimized off-the shelf whole tumor cell vaccine activates T cells that recognize a diverse antigen repertoire with potential to provide meaningful clinical benefit to patients with NSCLC**. Bernadette Ferraro. NEUVOGEN, San Diego, CA, United States.

American Association for Cancer Research® Special Conference in Cancer Research   10
TUMOR IMMUNOLOGY AND IMMUNOTHERAPY
In association with the Cancer Immunology (CIMM) Working Group
October 18-21, 2024 | Boston, MA

AACR Special Conference on
Tumor Immunology and Immunotherapy
October 18-21, 2024 | Boston, MA

AACR
American Association
for Cancer Research®

2403026E

B058 **Nous-209 off-the-shelf vaccine targets neoantigens mutations well represented both in primary and metachronous incident CRCs from Lynch syndrome patients**. Lorenzo De Marco. Nouscom Srl, Rome, Italy.

B059 **Signaling Requirements for Enhanced CD8+ T Cell Responses in mRNA Cancer Vaccine Immunotherapy**. Khalid Rashid. University of California Los Angeles, Los Angeles, CA, United States.

B060 **Enhanced therapeutic efficacy of a bioflavonoid loaded lipid nanoparticles via remodeling tumor microenvironment (TME) and KEAP1-NRF2 signaling in a murine breast tumor model**. Shakti Pattanayak. School of Medicine, Case Western Reserve University, Cleveland, OH, United States.

American Association for Cancer Research® Special Conference in Cancer Research
TUMOR IMMUNOLOGY AND IMMUNOTHERAPY
In association with the Cancer Immunology (CIMM) Working Group
October 18-21, 2024 | Boston, MA

11